A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Lindus Health has gone all-in on all-in-one CRO offerings. Less than a month after launching its All-in-One Women's Health ...

Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

Citizen’s partnership will work with CZI’s Rare As One project, a research and funding network that includes multiple patient ...

Medtronic has reported revenue gains across several of its medical device franchises, leading the company to nudge up its ...

Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

Canadian CRO Innovaderm is looking to expand its operations across the pond with the hiring of Ina Zschocke, Ph.D., as ...